Kala Pharmaceuticals Reports First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Kala Pharmaceuticals (KALA) Reports In-Line Q1 EPS, Revenues Beat
May 9, 2019 7:25 AM EDTKala Pharmaceuticals (NASDAQ: KALA) reported Q1 EPS of ($0.75), in-line with the analyst estimate of ($0.75). Revenue for the quarter came in at $1.39 million versus the consensus estimate of $1.1 million.
We are pleased with our results during the first quarter of 2019, particularly as it... More
